Immunotherapies
- PDF / 171,201 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 46 Downloads / 141 Views
1 S
Central nervous system complications: 2 case reports In a retrospective study of 19 patients, two patients [ages and sexes not stated] developed central nervous system complications during treatment with immune checkpoint inhibitors including ipilimumab, durvalumab or atezolizumab [routes, dosages and durations of treatment to reactions onsets not stated]. The patients received ipilimumab and durvalumab (n=1) and atezolimumab (n=1). Subsequently, the patients developed central nervous system complications with immune checkpoint inhibitors (CNS-ICI). Immunotherapies were discontinued, and unspecified corticosteroids were initiated [outcomes not stated]. Vogrig A, et al. Spectrum and treatment of central nervous system complications of immune checkpoint inhibitors. European Journal of Neurology 27 (Suppl. 1): 386 abstr. 803498382 EPR2200, May 2020. Available from: URL: https://onlinelibrary.wiley.com/doi/epdf/10.1111/ene.14307 [abstract]
»
Editorial comment: Details of case report of patient receiving atezolimumab have previously been published and processed for Adis PV [see Reactions 1815 p168; 803493242 ].
0114-9954/20/1819-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 29 Aug 2020 No. 1819
Data Loading...
